NCT07213674 2026-04-16
A Study of Xaluritamig Plus Abiraterone Versus Investigator's Choice in Participants With Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer
Amgen
Phase 3 Recruiting
Clinical Trials
15 trialsNCT06136650 2026-04-15
MK-5684-004
Merck Sharp & Dohme LLC
Phase 3 Recruiting
NCT02257736 2026-04-13
An Efficacy and Safety Study of Apalutamide (JNJ-56021927) in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone in Participants With Chemotherapy-naive Metastatic Castration-resistant Prostate Cancer (mCRPC)
Aragon Pharmaceuticals, Inc.
Phase 3 Active not recruiting
NCT03748641 2026-04-13
MAGNITUDE
Janssen Research & Development, LLC
Phase 3 Active not recruiting
NCT04497844 2026-04-13
AMPLITUDE
Janssen Research & Development, LLC
Phase 3 Active not recruiting
NCT06136624 2026-04-08
OMAHA-003
Merck Sharp & Dohme LLC
Phase 3 Recruiting
NCT06120491 2026-04-03
EvoPAR-PR01
AstraZeneca
Phase 3 Recruiting
NCT04493853 2026-04-01
CAPItello-281
AstraZeneca
Phase 3 Active not recruiting
NCT05171816 2026-03-11
Study on Olaparib Plus Abiraterone as First-line Therapy in Men With Metastatic Castration-resistant Prostate Cancer (China Cohort)
AstraZeneca
Phase 3 Active not recruiting
NCT06650579 2026-02-24
REVELUTION-2: Relugolix+Abiraterone Acetate (AA) Versus Leuprolide+AA Cardiac Trial
Emory University
Phase 3 Recruiting
NCT03732820 2026-01-29
Study on Olaparib Plus Abiraterone as First-line Therapy in Men With Metastatic Castration-resistant Prostate Cancer
AstraZeneca
Phase 3 Active not recruiting
NCT03009981 2025-12-18
A Study of Androgen Annihilation in High-Risk Biochemically Relapsed Prostate Cancer
Alliance Foundation Trials, LLC.
Phase 3 Completed
NCT04446117 2025-12-18
CONTACT-02
Exelixis
Phase 3 Active not recruiting
NCT02975934 2025-07-25
TRITON3
pharmaand GmbH
Phase 3 Completed
NCT03834519 2025-05-18
KEYLYNK-010
Merck Sharp & Dohme LLC
Phase 3 Completed